|
Dentin disk treatment We prepared dentin disks from caries-free human molars extracted, for periodontal reasons, from healthy adults, with informed consent, at Tokushima University Dental Hospital. To prepare the disks from the middle of the dentin, we removed the enamel with a high-speed water-cooled handpiece, then sectioned it with a low-speed water-cooled diamond saw Buehler Ltd., Evanston, IL ; to approximately 1.5 mm thick. To simulate hypersensitivity, we etched the dentin with 0.6 mol L HC1 for 1 min, to enlarge the tubules, which were then rinsed with distilled water for 1 min and used immediately for the experiments. We applied CPP solution to the specimens for 1 min with a cotton swab, then dried them with a separate swab. Various post-treatment solutions 1 mol L NaOH, from 0 to 0.1 mol L NaF ; were then applied with a cotton swab for 1 min.
I have read and understand everything outlined in this summer camp brochure. I agree not to hold The Competitive Edge, Ltd. or Pomfret School, or anyone associated with their wrestling camp program responsible or liable for any accident, medical, dental, or any other expense incurred as a result of my child's participation at camp. I have also read and agree to the camp regulations. In case of injury, you have my permission to give my child first aid or take him her to a doctor or hospital to be treated.
There is, therefore, an acknowledged need for additional changes for the better in NSCLC therapy, especially because new active agents such as vinorelbine, paclitaxel, and gemcitabine have provided only minor improvements in survival for disseminated disease in NSCLC patients 3, 47, 48 ; . Although not as significant a public health problem as lung cancer, neuroblastoma is a devastating central nervous system disease. Cisplatin-containing chemotherapy is frequently used for treatment of intermediate-to-high-risk neuroblastomas, but metastatic neuroblastoma patients still have a poor response rate. Improvements in treatment of disseminated neuroblastoma are clearly required. Squalamine in combination with cisplatin or with paclitaxel plus carboplatin enhances control of growth for both the MV-522 human lung tumor and the human SD neuroblastoma tumor as xenografts when compared with the cytotoxic agents alone. We have previously provided evidence that squalamine has specificity for endothelial cells and is thought to effectively drive activated endothelial cells into quiescence by a mechanism still to be fully elucidated 30, 31 ; . Not all endothelial cells appear to be sensitive to squalamine, however. The most sensitive cells appear to be those found in newly emerging or embryonic microvessels, vasculature that lacks accessory stromal cells, and extracellular matrix elements characteristic of mature blood vessels 30 ; . Embryonic tumor endothelium is characteristic of growing vessels in tumors soon after a population of tumor cells has been killed 27 ; . We consequently designed our MV-522 and SD tumor studies to provide squalamine treatment concurrent with initiating tumor cell kill with cisplatin or carboplatin plus paclitaxel. The addition of squalamine to platinum-based dosing improved the response of MV-522 and SD tumors to chemotherapy. However, there also appeared to be an increased toxicity when squalamine was used at high doses in combination. There is no evident overlap in toxicity for squalamine with platinum compounds and the deleterious interaction of these agents and.
Gemcitabine gemzar�
Hepatology 2003, 5 : 961- return to citation in text: rajagopalan v, daines wp, grossbard ml, kozuch p: gallbladder and biliary tract carcinoma: a comprehensive update, part oncology huntingt ; 2004, 18 : 889-9 return to citation in text: grunewald r, kantarjian h, keating mj, abbruzzese j, tarassoff p, plunkett w: pharmacollogically directed design of the dose rate and schedule of 2, 2-dideoxy-fluorocytidine gemcitabine ; administration in leukemia.
4, no 4, pages 581-586 doi: 1 1517 1465656 ; gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study petr karasek , tomas skacel , ilona kocakova , otakar bednarik , lubos petruzelka , bohuslav melichar , ivana bustova , vladimir spurny , tomas trason masaryk memorial cancer institute brno, oncology department, 656 53 brno, zluty kopec 7, czech republic.
Continuous infusion of the hormone Fig. 4B ; . In hypophysectomized male rats, GH given as two daily injections decreased AdoMet synthetase activity, whereas a continuous infusion increased the activity Fig. 5A ; . AdoMet synthetase mRNA levels decreased after GH treatment as two daily injections, but a continuous infusion did not significantly alter the mRNA level. Moreover, the difference between the two modes of GH administration did not reach statistical significance in the hypophysectomized male rats Fig. 5B and gemifloxacin.
The major symptom of PPH is significant abnormal vaginal blood loss as described above ; , which may be accompanied by one or more clinical signs and symptoms depending on the amount of blood loss. These may include palpitations, dizziness, tachycardia, weakness, sweating, restlessness, pallor and ultimately, collapse Schuurmans, MacKinnon, Lane, & Etches 2000.
Defect must be individually judged. It is self-evident that small, monocular and peripheral defects are less important than large and central defects. Defects covering corresponding parts in the two eyes, i.e. homonymous defects, are particularly dangerous to flying. 8.3 Methods of examination The visual field can be measured binocularly or, usually, monocularly. The most simple measurement, which can be performed without special equipment, is by so-called confrontation the expression is derived from the fact that the subject and the examiner face each other ; . The most often practised method is that designed by Donders and named after him. Here, the applicant and the examiner face each other at a distance of about one metre. Both cover the corresponding eye the right eye of one and the left of the other ; and look into each other's seeing eye. The examiner moves his hand from the periphery towards the center and compares his own seeing with that of the applicant; the latter tells as soon as he sees the hand. This test, of course, demands normal visual fields of the examiner. The visual field shall be tested in several meridians of each eye, preferably in the eight main meridians 12, 3, 6 and 9 o'clock and the oblique meridians in between ; . This way of testing the visual field is rough and insensitive and does not provide a basis for comparison or recording. Sensitivity can be increased by using a smaller object or by asking the applicant to tell whether the fingers are moving or steady. If, however, anything but large defects should be found, perimetry or campimetry should be used. These methods are also necessary for the precise recording of field defects. a Perimetry In the perimeter, an object of defined size and brightness is presented on a stable background. The background can be an arc moved in different meridians or, as most often today, a hemisphere. The object can be a stimulus patch moved by hand or a light dot projected on the background. If the perimeter has not its own illumination, it is essential that it is evenly illuminated by an external light source which must be kept unaltered between examinations. The eye to be examined is first centred in the perimeter by adjusting the head-and -chin rest. The applicant is told to fixate steadily on the fixation mark or light and to signal when the stimulus is seen. In the bowl perimeters, central fixation can be checked via a telescope. With a manual arc perimeter, a suitable target is moved by hand from the periphery until it is seen by the applicant. In this kinetic perimetry, several meridians are tested so that an isoptre for the object used can be mapped. With a large object of high contrast, the outer limits of the visual field are found. Using smaller objects of lower contrast, smaller isoptres are recorded as is neces sary in order to find subtle defects of retrochiasmal origin. Projection arc perimeters show a round or oval object which, likewise, is moved from the periphery towards the centre in various meridians. As with the objects moved by hand, at least eight meridians should be tested. If a scotoma is found, it can be mapped by moving the object from the centre of the defect in various directions. The arc perimeters have largely been replaced by the bowl perimeters. Here the subject is placed with his eye to be tested in the centre of a hemisphere which is evenly illuminated usually to 10 cd light dot of variable brightness and size can be presented anywhere within the hemisphere via a projection system. Most often performed is kinetic perimetry where a varying number of isoptres is recorded by steady movement of different objects in several meridians. Examination is fairly simple to perform and evaluate. Precision is high and even small defects are detectable by this kind of perimetry. Unfortunately, the apparatuses are rather expensive and gemtuzumab.
Gemcitabine 5fu
In all three cases we observed severe dyspnoea and bronchospasm, that required treatment discontinuation but one was probably due to gemcitabine and another had a protracting time after premedication.
13. Seidman AD. The evolving role of gemcitabine in the management of breast cancer. Oncology 2001; 60: 189198. Spielmann M, Llombart-Cussac A, Kalla S et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60: 303307. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353 Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 18581867. Seidman AD, Hudis CA, Albanell J et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 33533361. Bishop JF, Dewar J, Toner G et al. A randomized study of paclitaxel versus cyclophosphamide methotrexate 5-fluorouracil prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia New Zealand. Semin Oncol 1998; 24 Suppl 17 ; : 59. 19. Biganzoli L, Cufer T, Bruning P et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002; 20: 31143121. Kroep JR, Giaccone G, Tolis C et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 2000; 83: 10691076. Kroep JR, Giaccone G, Voorn DA et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 1999; 17: 2190. Cividalli A, Mauro F, Livdi E et al. Schedule dependent toxicity and efficacy of combined gemcitabine paclitaxel treatment in mouse adenocarcinoma. J Cancer Res Clin Oncol 2000; 126: 461467. Rothenberg ML, Sharma A, Weiis JR et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998; 9: 133138. Colomer R, Montero S, Lluch A et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6: 23562362. Colomer R, Llombart A, Lluch A et al. Paclitaxel gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol 2000; 27 1 Suppl 2 ; : 2024. 26. Cancer Therapy Evaluation Program. Common Toxicity Criteria, version 1.0. Bethesda, MA: National Cancer Institute 1999. 27. Longo DL, Duffey PL, De Vita VT et al. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991; 9: 20422051. Murad AM, Guimaraes RC, Aragao BC et al. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. J Clin Oncol 2001; 24: 264268. Theodossiou C, Cook JA, Fisher J et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998; 12: 825832. Isla D, Rosell R, Snchez JJ et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001; 19: 10711077. Sternberg CN, Calabr F, Pizzocaro G et al. Chemotherapy with an every2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92: 29932998. Lipton A, Ali SM, Leitzel K et al. Elevated serum Her-2 neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20: 14671472. Yamauchi H, O'Neill A, Gelman R et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2 c-neu protein. J Clin Oncol 1997; 15: 25182525 and gemzar.
Gemcitabine carboplatin ovarian
Value of gemcitabine cell lung cancer. Lung and policy for advanced.
Gemcitabine no prescription
A dozen bikers met on perfect February Saturday morning for an easy ride on the greenbelt only one casualty Suzanne's chain came off boo-hooo! ; , and everybody enjoyed lunch and Bloody Marys! ; at Duke's afterwards. Well, we'd earned it, right, folks? and genotropin.
Gemcitabine hci side effects temporary reduction in the production of blood cells.
Cambridge Centre for Molecular Recognition, Nuclear magnetic resonance relaxation studies of University Chemical poly hydroxybutyrate ; Laboratory, UK. in whole cells and in artificial granules and gentamicin
| Gemcitabine vinblastineAs Christians we believe our world view helps us understand the physical world God has created. This paper grew out of a concern that some engineering faculty are using certain teaching techniques in an attempt to impose non-Christian world views on their students. This problem first surfaced with engineering design courses. In a 1990 paper in Engineering Education, Culver, Woods, and Finch proposed monitoring the effectiveness of design instruction by the degree to which the students embrace a relativistic world view at the end of the course. Most engineering students are philosophically naive, and may easily be convinced of this perspective. Another aspect of this problem is shown by the changes many faculty have made in teaching freshman and sophomore engineering courses. Many engineering faculty have moved away from the traditional lecture method. They now use more active learning techniques, where small groups of students learn much of the course content through group activities. There is evidence that this approach helps the students learn more effectively. Both authors use active learning techniques in many of their classes. However, at the heart of this approach, there is a problem. It is based on a constructivist view of the world, where students construct their own reality as they solve problems as a team. If not guided correctly, students may come to completely erroneous conclusions about our physical world. They may be also convinced that their conclusions about reality are as good as that of the professor or textbook author. We recommend ways in which the good aspects of active learning can be utilized without buying into the dangerous world view that many of its proponents proclaim.
We don't know if gemcitabine helps after surgery as there is not any good research on this and gentian.
Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, Gahrton G. Benefit and Timing of Second Transplantations in Multiple Myeloma: Clinical Findings and Methodological Limitations in a European Group for Blood and Marrow Transplantation Registry Study, 1674 Morris DE, see Fried DB see Socinski MA Morris J, see Ajani JA Morris M, see Eifel PJ see Scher HI Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH. Phase II Study of Cisplatin and Vinorelbine in Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study, 3340 Morrow M, see Golub RM Morschhauser F, see Mounier N Morselli M, see Potenza L Mortimer JE, see Tripathy D Morton DL, see Lee JH see Takeuchi H Morton RF, see Goldberg RM Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present Status and Future Prospects for Adjuvant Therapy of Melanoma: Time to Build upon the Foundation of High-Dose Interferon Alfa-2b editorial ; , 11 Moschovi M, see French CA Moscinski L, see Johnson JL Moses MA, see Chan LW Mosley ST, see Rich TA Mossavar-Rahmani Y, see Chlebowski RT Motzer RJ, see Kondagunta GV Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma, 454 Motzer RJ. In Reply correspondence ; , 1158 Moul JW, see Amling CL see Scher HI Moullet I, see Hequet O Mounier N, Gisselbrecht C, Briere J, Haioun C, Feugier P, Offner F, Recher ` C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F. Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de I'Adulte, 2826 Mountain A, see Palmer DH Mouridsen H, Chaudri-Ross HA. In Reply correspondence ; , 3200 Mouridsen HT, see Ejlertsen B Mouridsen HT. Exemestane Following Tamoxifen in Postmenopausal Women With Primary Breast Cancer correspondence ; , 3833 Mourits MJE, see Buijs C Moyano J, see Bruera E Mrozek K, see Byrd JC see Marcucci G Muanza T, see Chan LW Muckaden MA, see Laskar S Mueller SP, see Antoch G Muennig P, see Mandelblatt JS Muggia FM, see Hochster H Muhr-Wilkenshoff F, see Kiewe P Mulders PFA, see Patard J-J Muler JH, McGinn CJ, Normolle D, Lawrence T, Brown D, Hejna G, Zalupski MM. Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer, 238 Mulhern RK, see Fouladi M see Merchant TE and gemcitabine.
Long term side effects of gemcitabine
|
Overall response rate compared with patients receiving best supportive care 8% versus 0%; P 0.0001 ; . Progression-free survival was also improved in the panitumumab arm hazard ratio, 0.54; 95% confidence interval, 0.44-0.66; P 1 109 ; . Panitumumab has also been evaluated in combination with irinotecan-based chemotherapy. At the 2006 American Society of Clinical Oncology gastrointestinal meeting, Hecht et al. 105 ; presented the results of a phase II study of panitumumab in combination with two different irinotecan-based regimens: bolus IFL and infusional FOLFIRI 5-FU leucovorin + irinotecan ; . Patients receiving panitumumab plus IFL had a response rate of 47%, a stable disease rate of 32%, and a median progression-free and overall survival of 5.6 and 16.8 months, respectively. Patients treated with panitumumab combined with FOLFIRI had a response rate of 33%, with stable disease in 46% of the patients and a median progressionfree survival of 10.9 months. Overall survival for this cohort of patients was not available at the time of this analysis. Other phase III studies with panitumumab are ongoing in the first-line and second-line settings, which will further define the role of this fully human antibody. Erlotinib. Erlotinib is a small-molecule quinazolinamine that reversibly inhibits the EGFR tyrosine kinase and prevents receptor autophosphorylation 106-108 ; . Erlotinib is approved in the United States, Europe, and several other countries as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. Approval of erlotinib was based on results from a large phase III trial in patients with advanced NSCLC following failure of prior chemotherapy in which single-agent erlotinib showed a significant survival benefit over placebo 109 ; . However, results from two earlier phase III trials showed no benefit from the addition of erlotinib to platinum-based chemotherapy as first-line treatment for advanced or metastatic NSCLC 110, 111 ; . In patients who had never smoked, however, there was a substantial survival benefit 112 ; . Evidence from some investigators has suggested that EGFR mutations may confer additional sensitivity to erlotinib and gefitinib in terms of response 113-115 ; , and thus may account for the limited efficacy observed in some clinical trials 110, 111 ; . However, although the presence of an EGFR mutation may increase responsiveness to erlotinib, it is not indicative of survival benefit. Phase II trials for erlotinib and gefitinib have reported correlations between responsiveness to EGFR inhibition and patient characteristics such as gender, histologic type, race or ethnic origin, and smoking status 109, 116-119 ; . Erlotinib is also approved in the United States in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy. This label extension was based on the results of a recent phase III trial in which erlotinib significantly improved survival when added to gemcitabine in patients with advanced pancreatic cancer 120 ; . Disease control rates were reported to be 58% and 49% for the erlotinib and placebo arms, respectively 120 ; . The recorded hazard ratio for survival 0.81; P 0.028 ; equates to a 19% reduction in the risk of death. Patients treated with erlotinib also had a 1-year survival rate of 23.8% versus 19.34% for patients receiving and ginger.
Gemcitabine more for_health_professionals
Bilirubin. The condition is associated with liver or gallbladder disease, or excessive destruction of red blood cells.
Fig. 2. Core temperature and motor activity during the heat stress challenge following 21 to 24 days of PTU treatment. Values are means SE. Horizontal bar "HEAT STRESS" ; denotes period of heat stress where ambient temperature Ta ; of chamber was increased from 23 to 34C. Repeated measures ANOVA: core temperature, treatment, F 4, 45 ; 32.8, P 0.0001; treatment time, F 32, 360 ; 4.6, P 0.0001; motor activity treatment, not significant NS treatment time, F 32, 360 ; 2.1, P 0.0008. Numbers in parentheses indicate sample size and ginkgo.
15. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., and Todd, G. C. Evaluation of the antitumor activity of gemcitabine 2 , 2 -difluoro-2 -deoxycytidine ; . Cancer Res., 50: 4417 4422, Burriss, H. A., III, Moore, M. J., Anderson, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomised trial. J. Clin. Oncol., 15: 24032413, 1997. Moore, M. J., Tannock, I. F., Ernst, D. S., Huan, S., and Murray, N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol., 15: 34413445, 1997. Stadler, W. M., Kuzel, T., Roth, B., Raghavan, D., and Dorr, F. A. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol., 15: 3394 3398, Lorusso, V., Pollera, C. F., Antimi, M., Luporini, G., Gridelli, C., Frassineti, G. L., Oliva, C., Pacini, M., and De Lena, M. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer, 34: 1208 1212, Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt. L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. Part 1, 50: 219 Fletcher, T. F. Anatomy of the pelvic viscera. Vet. Clin. N. Am., 4: 471 486, Shipley, L. A., Brown, T. J., Cornpropst, J. D., Hamilton, M., Daniels, W. D., and Culp, H. W. Metabolism and disposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug. Metab. Dispos., 20: 849 855, Caminier, G. W., and Smith, C. G. Studies of the enzymatic deamination of cytosine arabinoside. I. Biochem. Pharmacol., 14: 14051416, 1965. Storniolo, A. M., Allerheiligen, S. R., and Pearce, H. L. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin. Oncol., 24 2 Suppl. 7 ; : S7-2S7-7, 1997. 25. Plunkett, W., Huang, P., Searcy, C. E., and Gandhi, V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol., 23 5 Suppl. 10 ; : 315, 1996. 26. Lewis, C., Lawson, N., Rankin, E. M., Morrison, G., MacLean, A. B., Cordiner, J., Cassidy, J., Kerr, D. J, and Kaye, S. B. Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer. Cancer Chemother. Pharmacol., 26: 283287, 1990. Koontz, W. W., Jr., Prout, G. R., Jr., Smith, W., Frable, W. J., and Minnis, J. E. The use of intravesical thiotepa in the management of non-invasive carcinoma of the bladder. J. Urol., 125: 307312, 1981 and gemifloxacin.
Gemcitabine dosing
Draft of ballast track design standard. The adequacy of the prediction model was roughly verified by track site measurements continued for almost six years focused on track settlement. In this study, using the prediction model of track settlement, the effect of curative rail grinding to remove rail corrugations on track deterioration has been evaluated as well as the effect of ballast tamping. TRACK MAINTENANCE FROM A NOISE PERSPECTIVE IN THE CONTEXT OF EUROPEAN LEGISLATION, STANDARDS AND RESEARCH J Block and ginseng.
F7 SINGLE-AGENT PEMETREXED OR SEQUENTIALLY ADMINISTERED PEMETREXED GEMCITABINE AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER NSCLC ; IN ELDERLY PATIENTS OR PATIENTS INELIGIBLE FOR PLATINUM-BASED CHEMOTHERAPY: PRELIMINARY RESULTS OF A PHASE II RANDOMIZED TRIAL C. Gridelli, M. Reck, V. Gregorc, M. Migliorino, T.R. Muller, C. Manegold, A. Favaretto, E. Crucitta, M. Munoz, L. Cirri, L. Marini, A. Rossi, G. Koschel S.G. Moscati Hospital, Avellino; Krankenhaus Grosshansdorf, Grosshansdorf, Germany; San Raffaele Hospital, Milan, Italy; Forlanini Hospital, Rome; Kliniken des Main-Taunus-Kreises, Hofheim, Germany; Universitaets klinikum Mannheim; Chir. Klinik, Mannheim, Germany; University Hospital, Padova; Eli Lilly & Co., Florence, Italy; Eli Lilly & Co., Madrid, Spain; Allgemeines Krankenhaus Harburg, Hamburg, Germany Background: Because elderly patients pts ; may tolerate combination chemotherapy poorly, single-agent chemotherapy is often the preferred treatment. This study evaluated the efficacy primary objective: time to progressive disease[TTPD] ; and toxicity of single-agent pemetrexed P ; , and sequential pemetrexed gemcitabine P G ; for the treatment of advanced NSCLC in elderly pts 70 ; or pts ineligible for platinum-based chemotherapy. Methods: Chemonaive pts with stage IIIB IV NSCLC and an ECOG-PS 0-2 were randomized to P 500 mg m2 on day 1 every 3 weeks for 8 cycles P arm ; , or P 500 mg m2 for cycles 1 and 2 followed by G 1200 mg m2 on days 1 and 8 of cycles 3 and 4 P G arm this 4-cycle schedule was repeated once for a total of 8 cycles. Vitamin B12 and folic acid supplementation were required on both study arms. Results: A total of 92 pts were enrolled: 46 pts 7 with stage IIIB, 39 with stage IV ; on the P arm and 46pts 8 with stage IIIB, 38 with stage IV ; on the P G arm. Of the 92 pts, 81 40 P, 41 P were evaluable for efficacy and toxicity. The median TTPD was similar for both arms 4.2 and 4.1 months for P and P G, respectively ; . Partial response was observed in 5 12.5% ; pts 3 unconfirmed after 1 month ; treated with P and 5 12.2% ; pts 2 unconfirmed ; treated with P G. Nine 22.5% ; pts on the P arm and 8 19.5% ; on the P G arm had stable disease. Hematologic toxicity was mild: grade 3 neutropenia in 3 7.5% ; pts on the P arm 2 pts with febrile neutropenia grade 3 4 thrombocytopenia in 1pt per arm 2.5% and 2.4%, respectively grade 3 4 anemia in 3 7.5% ; and 2 4.9% ; pts on the P and P G arm, respectively. Grade 3 4 non-hematologic toxicities, allergic reaction, diarrhea, melena, gastritis and anorexia occurred in 1 2.5% ; pt treated with P. In patients treated with P G, fatigue and abdominal pain occured in 1 pt 2.4% ; and rash in 2 pts 4.9% ; . Conclusions: Preliminary results show that single-agent P and sequential P G are active and well tolerated in this subset of pts with advanced NSCLC. The overall survival analysis is ongoing. limiting toxicity, observed in 36% of pts. Moreover, grade 3-4 anemia was observed in 17% and grade 3-4 thrombocytopenia in 12% of pts, respectively. One PS 2 patient died for grade 4 haematological toxicity after the first cycle. Median time to disease progression was 9 weeks range 113 ; . Median survival for the entire group was 26 weeks range 1 91 + ; with 14% of pts alive at 1 yr. Conclusions: In conclusion, the combination of topotecan and ifosfamide demonstrated antitumor activity with modest side effect profile in patients with refractory NCSLC, with an overall disease control PR + MR 50.7%. Nevertheless, the still low response rate and the shortness of median survival claim for more effective second line treatments in this disease.
Side effects of Gemcitabine
Gemcitabine neutropenia
Health reimbursement arrangement, hyperventilation cure, intussusception diagram, oncology nurse practitioner salary and isotope helium. Mrna functions, legionella urinary antigen test, orifice flow meter and marfan syndrome other names or hamstring back of knee pain.
Gemcitabine and carboplatin for ovarian cancer
Gemcitabie, gemcitabone, gecitabine, gemcitxbine, gemcitsbine, gdmcitabine, gemcittabine, gemictabine, gemcitabune, geemcitabine, gemcitqbine, gemcitavine, gemmcitabine, gemcitabjne, gemcitbaine, gemciabine, gemcitabibe, gemcifabine, gecmitabine, vemcitabine.
Gemcitabine for breast cancer
Gemcitabine gemzar�, gemcitabine 5fu, gemcitabine carboplatin ovarian, gemcitabine no prescription and gemcitabine vinblastine. Long term side effects of gemcitabine, gemcitabine more for_health_professionals, gemcitabine dosing and side effects of gemcitabine or gemcitabine neutropenia.
|
